{"id":33222,"date":"2025-05-12T11:08:18","date_gmt":"2025-05-12T09:08:18","guid":{"rendered":"https:\/\/ggba.swiss\/?p=33222"},"modified":"2025-05-12T11:08:20","modified_gmt":"2025-05-12T09:08:20","slug":"haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/","title":{"rendered":"HAYA Therapeutics raises USD 65 million to advance RNA-guided therapies for chronic disease"},"content":{"rendered":"\n<p>The financing round, co-led by <a href=\"https:\/\/sofinnovapartners.com\/\">Sofinnova Partners<\/a> and <a href=\"https:\/\/earlybird.com\/\">Earlybird Venture Capital<\/a>, includes participation from <a href=\"https:\/\/www.lilly.com\/\">Eli Lilly and Company<\/a>, <a href=\"https:\/\/www.athos-cap.com\/\">ATHOS<\/a>, <a href=\"https:\/\/nd.capital\/\">+ND Capital<\/a>, <a href=\"https:\/\/www.are.com\/venture-investments.html\">Alexandria Venture Investments<\/a>, and <a href=\"https:\/\/lifelinkventures.com\/\">LifeLink Ventures<\/a>, alongside existing investors <a href=\"https:\/\/www.apollo.vc\/\">Apollo Health Ventures<\/a>, Broadview-affiliate <a href=\"https:\/\/broadviewventures.org\/longview-ventures\/\">Longview Ventures<\/a>, <a href=\"https:\/\/4seeventures.ch\/\">4see ventures<\/a>, <a href=\"https:\/\/www.berninabioinvest.com\/\">BERNINA Bioinvest<\/a>, and <a href=\"https:\/\/www.schroderscapital.com\/en\/global\/professional\/\">Schroders Capital<\/a>.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.hayatx.com\/\">HAYA Therapeutics<\/a> will use the new capital to initiate clinical trials for its lead candidate, HTX-001, a first-in-class long non-coding RNA (lncRNA)-targeting therapy for heart failure. The initial indication is non-obstructive hypertrophic cardiomyopathy (nHCM), a condition with limited treatment options. In parallel, the company will continue to develop its proprietary platform and pipeline, targeting diseases such as pulmonary fibrosis, obesity, and other chronic and age-related conditions.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">A next-generation platform decoding the dark genome<\/h4>\n\n\n\n<p>HAYA\u2019s approach focuses on the regulatory genome\u2014the 98% of DNA that does not code for proteins but controls gene expression and cell identity. The company has built a comprehensive atlas of this so-called \u201c<a href=\"https:\/\/www.bbc.com\/future\/article\/20230412-the-mystery-of-the-human-genomes-dark-matter\">dark genome<\/a>,\u201d using multimodal genomics, machine learning, and computational biology to map and modulate disease-driving cell states.<\/p>\n\n\n\n<p>By targeting lncRNAs specific to particular tissues and disease states, HAYA aims to reprogram pathological cells at the source, offering therapies with higher precision and fewer side effects than traditional approaches. The company\u2019s RNA-guided therapeutics are designed to be scalable, fast to develop, and deeply programmable.<\/p>\n\n\n\n<p>HAYA\u2019s recent <a href=\"https:\/\/ggba.swiss\/en\/haya-therapteutics-enters-major-collaboration-to-advance-rna-based-drug-discovery-for-metabolic-diseases\/\">partnership with Eli Lilly<\/a>, one of the largest collaborations in the field of regulatory genomics, further validates its platform\u2019s potential.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HAYA Therapeutics, a precision medicine company based at Biop\u00f4le in Lausanne, has closed a USD 65 million Series A funding round to accelerate the clinical development of its RNA-guided therapies and expand its regulatory genome platform.<\/p>\n","protected":false},"author":6,"featured_media":33223,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,890,883,911,886],"class_list":["post-33222","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-healthcare","tag-oncology","tag-pharma","tag-rd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HAYA Therapeutics raises USD 65 million | GGBa<\/title>\n<meta name=\"description\" content=\"HAYA Therapeutics, a precision medicine company based at Biop\u00f4le in Lausanne, has closed a USD 65 million Series A funding round.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HAYA Therapeutics raises USD 65 million | GGBa\" \/>\n<meta property=\"og:description\" content=\"HAYA Therapeutics, a precision medicine company based at Biop\u00f4le in Lausanne, has closed a USD 65 million Series A funding round.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-12T09:08:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T09:08:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"HAYA Therapeutics raises USD 65 million to advance RNA-guided therapies for chronic disease\",\"datePublished\":\"2025-05-12T09:08:18+00:00\",\"dateModified\":\"2025-05-12T09:08:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/\"},\"wordCount\":251,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Financing\",\"Healthcare\",\"Oncology\",\"Pharma\",\"R&amp;D\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/\",\"url\":\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/\",\"name\":\"HAYA Therapeutics raises USD 65 million | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg\",\"datePublished\":\"2025-05-12T09:08:18+00:00\",\"dateModified\":\"2025-05-12T09:08:20+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"HAYA Therapeutics, a precision medicine company based at Biop\u00f4le in Lausanne, has closed a USD 65 million Series A funding round.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"The company\u2019s co-founders, CEO Samir Ounzain and CTO Daniel Blessing, received an award at the Festival of the Future in Munich. | \u00a9 HAYA Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HAYA Therapeutics raises USD 65 million to advance RNA-guided therapies for chronic disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HAYA Therapeutics raises USD 65 million | GGBa","description":"HAYA Therapeutics, a precision medicine company based at Biop\u00f4le in Lausanne, has closed a USD 65 million Series A funding round.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/","og_locale":"en_US","og_type":"article","og_title":"HAYA Therapeutics raises USD 65 million | GGBa","og_description":"HAYA Therapeutics, a precision medicine company based at Biop\u00f4le in Lausanne, has closed a USD 65 million Series A funding round.","og_url":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-05-12T09:08:18+00:00","article_modified_time":"2025-05-12T09:08:20+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"HAYA Therapeutics raises USD 65 million to advance RNA-guided therapies for chronic disease","datePublished":"2025-05-12T09:08:18+00:00","dateModified":"2025-05-12T09:08:20+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/"},"wordCount":251,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg","keywords":["Biotech","Financing","Healthcare","Oncology","Pharma","R&amp;D"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/","url":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/","name":"HAYA Therapeutics raises USD 65 million | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg","datePublished":"2025-05-12T09:08:18+00:00","dateModified":"2025-05-12T09:08:20+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"HAYA Therapeutics, a precision medicine company based at Biop\u00f4le in Lausanne, has closed a USD 65 million Series A funding round.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/05\/Haya-Therapeutics-65-millions-1180x811-1.jpg","width":1180,"height":811,"caption":"The company\u2019s co-founders, CEO Samir Ounzain and CTO Daniel Blessing, received an award at the Festival of the Future in Munich. | \u00a9 HAYA Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/haya-therapeutics-raises-usd-65-million-to-advance-rna-guided-therapies-for-chronic-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"HAYA Therapeutics raises USD 65 million to advance RNA-guided therapies for chronic disease"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/33222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=33222"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/33222\/revisions"}],"predecessor-version":[{"id":33226,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/33222\/revisions\/33226"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/33223"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=33222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=33222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=33222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}